Hong Kong Stock Alert | CLOVER BIO-B (02197) Opens Up Over 5% on Positive Preliminary Clinical Trial Data

Stock News10-15

CLOVER BIO-B (02197) opened significantly higher by over 5%. As of press time, the stock was up 5.67% to HK$2.98, with a trading volume of HK$1.3738 million.

On the news front, Clover Biopharmaceuticals announced positive preliminary data from two ongoing clinical trials, including:

A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 and SCB-1033 in a head-to-head comparison with SCB-1019, targeting elderly populations who had not previously received any RSV vaccines; and a Phase I clinical trial conducted in the United States for a head-to-head evaluation of repeat vaccination with SCB-1019 versus AREXVY, targeting elderly populations who had received their first AREXVY vaccination at least two influenza seasons prior to enrollment.

Based on these positive Phase I clinical trial results, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166800025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166800025","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Alert | CLOVER BIO-B (02197) Opens Up Over 5% on Positive Preliminary Clinical Trial Data","media":"Stock News","content":"<p>CLOVER BIO-B (02197) opened significantly higher by over 5%. As of press time, the stock was up 5.67% to HK$2.98, with a trading volume of HK$1.3738 million.</p>\n<p>On the news front, Clover Biopharmaceuticals announced positive preliminary data from two ongoing clinical trials, including:</p>\n<p>A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 and SCB-1033 in a head-to-head comparison with SCB-1019, targeting elderly populations who had not previously received any RSV vaccines; and a Phase I clinical trial conducted in the United States for a head-to-head evaluation of repeat vaccination with SCB-1019 versus AREXVY, targeting elderly populations who had received their first AREXVY vaccination at least two influenza seasons prior to enrollment.</p>\n<p>Based on these positive Phase I clinical trial results, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | CLOVER BIO-B (02197) Opens Up Over 5% on Positive Preliminary Clinical Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | CLOVER BIO-B (02197) Opens Up Over 5% on Positive Preliminary Clinical Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-15 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOVER BIO-B (02197) opened significantly higher by over 5%. As of press time, the stock was up 5.67% to HK$2.98, with a trading volume of HK$1.3738 million.</p>\n<p>On the news front, Clover Biopharmaceuticals announced positive preliminary data from two ongoing clinical trials, including:</p>\n<p>A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 and SCB-1033 in a head-to-head comparison with SCB-1019, targeting elderly populations who had not previously received any RSV vaccines; and a Phase I clinical trial conducted in the United States for a head-to-head evaluation of repeat vaccination with SCB-1019 versus AREXVY, targeting elderly populations who had received their first AREXVY vaccination at least two influenza seasons prior to enrollment.</p>\n<p>Based on these positive Phase I clinical trial results, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1166800025","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166800025","pubTimestamp":1760492060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOVER BIO-B (02197) opened significantly higher by over 5%. As of press time, the stock was up 5.67% to HK$2.98, with a trading volume of HK$1.3738 million. On the news front, Clover...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B","BK1161":"生物科技"},"translate_title":"港股快讯|三叶草生物-B(02197)初步临床试验数据利好开盘超5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"CLOVER BIO-B (02197) opened significantly higher by over 5%. As of press time, the stock was up 5.67% to HK$2.98, with a trading volume of HK$1.3738 million.\nOn the news front, Clover Biopharmaceuticals announced positive preliminary data from two ongoing clinical trials, including:\nA Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 and SCB-1033 in a head-to-head comparison with SCB-1019, targeting elderly populations who had not previously received any RSV vaccines; and a Phase I clinical trial conducted in the United States for a head-to-head evaluation of repeat vaccination with SCB-1019 versus AREXVY, targeting elderly populations who had received their first AREXVY vaccination at least two influenza seasons prior to enrollment.\nBased on these positive Phase I clinical trial results, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166800025","isCrawlerRequest":true}